Search

for
Search:

Glossary Carboplatin

chemotherapy drug that interferes with cancer cell DNA

Carboplatin is a chemotherapy drug used to treat various types of cancer, including ovarian, lung, and head and neck cancers. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. While effective, it can cause side effects such as hair loss (alopecia), nausea, and decreased blood cell counts.

Research

5 / 243 results

research Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment

1 citations , September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies”

This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.

research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer

January 2025 in “Recent Patents on Anti-Cancer Drug Discovery”

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

research Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia

January 2022 in “eJournal Kedokteran Indonesia”

In this cross-sectional study, researchers found no significant difference in effectiveness between paclitaxel-carboplatin and pemetrexed-carboplatin for treating pulmonary adenocarcinoma with negative EGFR mutations, but paclitaxel-carboplatin was more cost-effective and associated with more frequent severe haematological toxicities.

research The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

5 citations , January 2024 in “Journal of Cancer”

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

research The clinical observation of first-line docetaxel and carboplatin treatment for elderly patients with non-selective non-small-cell lung cancer

January 2012 in “Journal of Clinical Medicine in Practice”

This study found that first-line treatment with docetaxel and carboplatin was safe and effective for elderly patients with advanced non-selective non-small-cell lung cancer, showing an overall efficacy rate of 47.87%.

View more "carboplatin" in research →

Learn

— no results

Community Join

— no results

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →